Treatment of Advanced Intrahepatic Cholangiocarcinoma

ICC Clinical Trial

— TAICC  

Official title:

The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03940378
• Other study ID #: LEVICC-001
• Status: Recruiting
• Phase: Phase 3
• Start date: February 1, 2019
• Est. completion date: February 1, 2023

Study information

• Verified date: May 2019
• Source: The First Affiliated Hospital of Zhengzhou University
• Contact: Zujiang Yu, pro
• Phone: 0086-0371-67966942
• Email: johnyuem[@]zzu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.

Description:

Intrahepatic cholangiocarcinoma(ICC) ,a kind of Hepatocellular carcinoma, is the sixth most common cancer and thesecond leading cause of cancer-related deaths in the world.Currently, Surgical resection is still the main treatment methods of early the ICC, but that is high recurrent . Levamisole Hcl is a broad spectrum of intestinal worm medicine, our previous study have found levamisole could significantly promote the apoptosis of bile duct cancer cells, restrain the progress of the bile duct carcinoma in clinic and prolong survival time.This drug is applicable to a variety of reasons caused by intrahepatic bile duct carcinoma and extrahepatic bile duct carcinoma,so we carry out the study to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 152
• Est. completion date: February 1, 2023
• Est. primary completion date: February 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 1. Ages 18-65 years

• 2. The diagnosis of ICC: in accordance with "diagnostic and treating standards on primary liver cancer" or histological/cytological diagnosis of primary liver cancer

• 3. Un-resectable HCC : patients with developing primary liver cancer of Barcelona stage(BCLC) B; multiple nodules (less than 5, the total diameter of less than 20 cm), no invasion, no symptoms;refusing open surgical treatment and volunteering for the treatment

• 4. The First-line system therapy failure (or residual lesion) from the group of this study a signed informed consent (time) for 2 weeks or more basic returned to normal and adverse events (NCI CTCAE ? level or less);

• 5. Child-Pugh liver function class A/B(score: =7)

• 6. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale in one week before admission

• 7. Estimated survival time > 3 months

• 8. HBV DNA#2000 IU/ml#10^4 copies/ml); or HBV DNA=2000 IU/ml and are accepting effective antiviral therapy

• 9. The major organ function is normal. that is meeting the following standards:

1. Blood routine examination: (No blood transfusion, no G-CSF and no medication were corrected within 14 days before screening)

a.HB=80g/L# b.ANC=1.5×109/L#c.PLT=50×109/L#

2. Biochemical examination: (ALB was not transfused within 14 days before screening) a.ALB =29 g/L# b.ALT#AST<5ULN#c.TBIL =3ULN#d.creatinine

• 1.5ULN( albumin and bilirubin, two indicators of Child-Pugh liver function class, can only have one for 2 points)

• 10. For women of childbearing age, the results of serum/urine pregnancy tests must be negative within 7 days before initiation of treatment. All men and women who participate in the study have to take reliable contraceptive measures within the trial and eight weeks after the trial is completed

• 11. volunteers must signed informed consent

Exclusion Criteria:

• 1. With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood =#++#

• 2. Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix

• 3. Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before)

• 4. Patients with an allergic history of Levamisole Hydrochloride and Anlotinib Hydrochloride Capsules

• 5. The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic pressure#90 mmHg)

• 6. Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men = 450 ms; women = 470 ms)

• 7. Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF#50%

• 8. Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs

• 9. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study

• 10. Dysfunction of blood coagulation(INR#2.0 or PT# 16s#APTT > 43s#TT > 21s#Fbg < 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score =2

• 11. Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present

• 12. Urine routine showed that urine protein =++ or the urine protein in 24 hours#1.0 g

• 13. Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study.

• 14. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives

• 15. Patients with mental sickness or the history of psychotropic drug abuse

• 16. Patients with severe infection (unable to control the infection effectively)

• 17. The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year)

• 18. The researchers believe that any other factors unsuitable for entering into the study.

Related Conditions & MeSH terms

• Cholangiocarcinoma
• ICC

Intervention

Drug:
• Levamisole Hydrochloride
Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
• Anlotinib Hydrochloride Capsules
Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (8)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Zhengzhou University	Anyang Tumor Hospital, First Affiliated Hospital of Xinjiang Medical University, Luoyang Central Hospital, Nanyang Central Hospital, pinmei Group General Hospital, Sanmenxia Central Hospital, Third People's Hospital of Jiaozuo

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Disease Control Rate (DCR)	the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease	28 days
Other	Objective Response Rate(ORR)	Proportion of patients with reduction in tumor burden of a predefined amount	28 days
Other	The change of AFP biomarker	Concentration of AFP biomarker change in tumor markers	approximately 24 months
Primary	Progression-free Survival	Time from start of treatment until the first documented event of symptomatic progression or death.	24 months
Secondary	Overall Survival	Time from start of treatment to death from any cause, or last known date of survival	48 months